| 25.36 0.2 (0.79%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 31.43 | 1-year : | 36.71 |
| Resists | First : | 26.9 | Second : | 31.43 |
| Pivot price | 25.78 |
|||
| Supports | First : | 24.36 | Second : | 22.79 |
| MAs | MA(5) : | 25.72 |
MA(20) : | 25.25 |
| MA(100) : | 24.57 |
MA(250) : | 23.81 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 55.5 |
D(3) : | 64.1 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 27.65 | Low : | 18.79 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PCRX ] has closed above bottom band by 31.5%. Bollinger Bands are 25.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.59 - 25.77 | 25.77 - 25.91 |
| Low: | 24.84 - 25.03 | 25.03 - 25.18 |
| Close: | 25.11 - 25.41 | 25.41 - 25.64 |
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Fri, 11 Sep 2026
Pacira Biosciences (NASDAQ:PCRX): An Undervalued Value Stock Backed by Cash Flow and Balance Sheet Strength - ChartMill
Wed, 09 Sep 2026
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Wed, 09 Sep 2026
Five new employees receive Pacira stock awards, vesting over four years - Stock Titan
Thu, 03 Sep 2026
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Mon, 17 Aug 2026
Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026 - Stock Titan
Sun, 09 Aug 2026
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 40 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 113.4 (%) |
| Shares Short | 7,300 (K) |
| Shares Short P.Month | 6,960 (K) |
| EPS | 0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.87 |
| Profit Margin | 1.9 % |
| Operating Margin | 6.1 % |
| Return on Assets (ttm) | 1.4 % |
| Return on Equity (ttm) | 2 % |
| Qtrly Rev. Growth | 6.1 % |
| Gross Profit (p.s.) | 14.82 |
| Sales Per Share | 18.71 |
| EBITDA (p.s.) | 3.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 188 (M) |
| Levered Free Cash Flow | 98 (M) |
| PE Ratio | 72.45 |
| PEG Ratio | 11.2 |
| Price to Book value | 1.5 |
| Price to Sales | 1.35 |
| Price to Cash Flow | 5.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|